Children and Adolescent Patients with Variants in the *ATP1A3*-encoded Sodium-Potassium ATPase Alpha-3 Subunit Demonstrate an Impaired QT Response to Bradycardia and Predisposition to Sinus Node Dysfunction

Short Title: Abnormal QT and QTc Dynamics in AHC

Meredith K. Srour, BA[1]; Minu-Tshyeto K. Bidzimou, BA[1,2]; Padmapriya Muralidharan, PhD[1]; Saige M. Mitchell, BS[1]; Mary E. Moya-Mendez, MD[1]; Lauren E. Parker, BS[1]; Gabriela Reyes Valenzuela, MD[3]; Roberto Caraballo, MD[3]; Giacomo Garone, MD[4]; Federico Vigevano, MD[4]; Sarah Weckhuysen, MD PhD[5,6,7]; Charissa Millevert, MD[5,6]; Monica Troncoso, MD[8]; Mario Matamala, MD[8]; Simona Balestrini, MD PhD[9,10]; Sanjay M. Sisodiya, PhD FRCP[9]; Josephine Poole, MSc[9]; Claudio Zucca, MD[11]; Eleni Panagiotakaki, MD PhD[12]; Maria T. Papadopoulou, MD[12]; Sébile Tchaicha, MS[12,14]; Matthildi Athina Papathanasiou Terzi[12]; Marta Zawadzka, MD PhD[13]; Maria Mazurkiewicz-Bełdzińska, MD[13]; Carmen Fons, MD PhD[14]; Jennifer Anticona, MD[14]; Elisa De Grandis, MD[15,16]; Ramona Cordani, MD[15,16]; Livia Pisciotta, MD, PhD[17]; Sergiu Groppa, MD[18]; Sandra Paryjas, MD[18]; Francesca Ragona, MD[19]; Elena Mangia, RN[19]; Tiziana Granata, MD[19]; Andrey Megvinov, PhD[20]; Rosaria Vavassori, PhD[20,21,22]; Mohamad A. Mikati, MD[23]; Andrew P. Landstrom, MD, PhD[1,2#]

[1]Department of Pediatrics, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, United States.
[2]Department of Cell Biology, Duke University School of Medicine, Durham, North Carolina, United States.
[3]Hospital Nacional de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
[4]Division of Neurology, Bambino Gesù Children's Hospital, Rome, Italy
[5]Department of Neurology, Antwerp University Hospital, Antwerp, Belgium
[6]Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
[7]Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium
[8]Child Neurology Service, Hospital San Borja Arriarán, University of Chile, Santiago, Chile
[9]Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London WC1N 3BG and Chalfont Centre for Epilepsy, London, Bucks, United Kingdom
[10]Neuroscience Department, Meyer Children's Hospital, European Reference Network ERN EpiCARE, 50139, Florence, Italy
[11]Clinical Neurophysiology Unit, IRCCS "E. Medea", Via Don L. Monza 20, 23842 Bosisio Parini (LC), Italy
[12]Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospitals of Lyon, Member of ERN EpiCARE, France
[13]Department of Developmental Neurology, Medical University of Gdansk, ul. Debinki 7, 80-952, Gdansk, Poland
[14]Pediatric Neurology Department, Hospital Sant Joan de Déu, Full Member of ERN EpiCare, Barcelona University, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
[15]Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
[16]Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
[17]Unit of Child Neuropsychiatry, ASST Fatebenefratelli Sacco, Milan, Italy
[18]Clinic of Neurology, Johannes Gutenberg University of Mainz, Mainz, Germany
[19]Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; Member of ERN EpiCARE, Via Celoria 11, 20133 Milan, Italy
[20]Euro-Mediterranean Institute of Science and Technology (I.E.ME.S.T.), Palermo, Italy; Informatics Department www.iemest.eu

[21]IAHCRC International Research Consortium, Data Management www.iahcrc.net

[22]European Reference Network EpiCARE-ERN, Patient Advocacy Group (ePAG) www.epi-care.eu

[23]Department of Pediatrics, Division of Neurology, Duke University School of Medicine, Durham, North

Carolina, United States.

#Corresponding Author:

Andrew P. Landstrom, MD, PhD

Duke University Medical Center

Box 2652

Durham, North Carolina, 27710

United States

Email: andrew.landstrom@duke.edu

Phone: (919) 684-3028 Fax: (919) 385-9329

Word Count: 3895

ABSTRACT

Background: Alternating hemiplegia of childhood (AHC) is a rare disorder with both neurologic and cardiac

manifestations. The ATP1A3-D801N variant is associated with a pathologically short QT interval and risk

of ventricular arrhythmia following bradycardia; however, the mechanism of this remains unknown. We

investigated the relationship between heart rate (HR), QT, and QTc, hypothesizing that individuals with

ATP1A3-D801N have abnormal, impaired shortening of QT and QTc at lower HR leading to arrhythmia

predisposition.

Methods: We performed a retrospective observational study of individuals who underwent clinical

evaluation, Holter monitoring, and genetic testing for AHC at Duke University Hospitals. We also compiled

a group of healthy individuals as a control cohort. A larger, worldwide cohort of individuals with *ATP1A3*-

related phenotypes was compiled to investigate sinus node dysfunction. Linear regression analysis was then

performed.

Results: The cohort consisted of 44 individuals with *ATP1A3*-related phenotypes with 81 Holter recordings

(52.27% female; mean age at first Holter 8.04 years, range 0.58 – 33 years), compared to 36 healthy

individuals with 57 Holter recordings (52.78% female; mean age at first Holter 9.84 years, range 0.08 – 38

years). Individuals with ATP1A3-D801N had reduced prolongation of QT at lower HR, manifest as a

significantly lower slope for HR vs QT compared to healthy (P<0.0001). This resulted in a significantly

higher slope of the relationship for HR vs QTc compared to healthy (P<0.0001). Individuals with *ATP1A3*-

related phenotypes and baseline QTc <350 milliseconds (ms) had increased shortening of QT and QTc at

lower HR compared to those with normal QTc (P=0.003; P=0.001). Among worldwide cases, 3 out of 131

individuals with *ATP1A3*-related phenotypes required device implantation and/or had sinus pauses >4

seconds.

Conclusions: Individuals with the ATP1A3-D801N variant exhibit paradoxical shortening of QT and QTc

at lower HR, which contribute to an increased risk of arrhythmias during bradycardia. This is exacerbated

by an underlying risk of sinus node dysfunction.

<u>Non-Standard Abbreviations and Acronyms</u>

AHC: alternating hemiplegia of childhood

ATP1A3: gene encoding for the alpha-3 subunit of sodium-potassium ATPase

ATP1A3-D801N: D801N missense variant in *ATP1A3*-encoded ATP1A3

ATP1A3 Non-D801N: missense single nucleotide variants, not including D801N, in *ATP1A3*-encoded

ATP1A3

ATP1A3 LOF: presumed loss of function variants in *ATP1A3*-encoded ATP1A3

ATP1A3 Neg: no pathogenic or likely pathogenic variant identified in *ATP1A3*

QTc: corrected QT interval

HR: heart rate

BPM: beats per minute

SUDEP: sudden unexplained death in epilepsy

<u>Clinical Perspective:</u>

What is Known:

- Individuals with ATP1A3-D801N have a short baseline QTc.

- Two individuals with AHC experienced ventricular fibrillation following bradycardia.

What the Study Adds:

- The QT and QTc shorten to a greater extent at lower heart rate in individuals with ATP1A3-D801N
than in healthy individuals.

- Individuals with *ATP1A3*-related phenotypes and QTc <350ms show greater impairment of QT and
QTc dynamics than those with normal QTc.

- There is low prevalence of device implantation and significant sinus pauses in individuals with
ATP1A3-related phenotypes, with a relatively greater prevalence in those with ATP1A3-D801N.

INTRODUCTION

Individuals with abnormally fast cardiac repolarization, manifest as a shortened QT interval, are at an increased risk of atrial and ventricular arrhythmias which can be life-threatening[1-3]. As heart rate (HR) can modulate QT interval, diagnostic criteria center around a corrected QT (QTc) which measures ventricular repolarization and normalizes it to heart rate, often using Bazett's correction[4,5]. A diagnosis of short QT syndrome (SQTS) uses Gollob's criteria, a point-based diagnostic system with increasing points given for QTc <370, <350, and <330ms, respectively[6]. In addition to short QTc, SQTS can also present with sinus node dysfunction, with prior case reports describing episodes of sinus arrest and junctional rhythm[7,8]. Further, there is an emerging relationship between HR and QT response in SQTS. Prior work has shown that individuals with SQTS display blunted response of QT to changes in HR when compared to healthy individuals[9-11]. However, the genetic and mechanistic causes of SQTS are often unclear. While believed to be heritable, only a minority of patients with SQTS are genotype positive for causative genes[2,12]. Thus, there is a need to identify new genes and new mechanisms of SQTS development.

Alternating hemiplegia of childhood (AHC) is a rare condition which typically manifests prior to 18 months of age with episodic hemiplegia and/or quadriplegia, dystonia, oculomotor abnormalities, seizures, dysautonomia, and sudden unexplained death in epilepsy (SUDEP)[13,14]. We have previously found that individuals with AHC have cardiac features that are similar to those with SQTS, including a shortened QTc on electrocardiogram (ECG)[15-18] and sinus node dysfunction that may require device implantation[19,20]. Specifically, we found that individuals hosting ATP1A3-D801N, the most common missense variant among those with AHC, are uniquely predisposed to short QTc interval and ventricular arrhythmias associated with bradycardia, particularly during periods of anesthesia or sedation[15,18,21,22]. Taken together, this work suggests that SUDEP in AHC is due to the short QT phenotype; however, the link between bradycardia and arrhythmia generation remains unknown. Exploring this question will yield important new insight into SQTS, and the modulators of cardiac repolarization, more broadly.

With this in mind, we sought to investigate QT and QTc dynamics in AHC with respect to HR through linear regression analysis, which has been previously utilized for this purpose[9,23-27]. We evaluated

cardiac Holter recordings of individuals with AHC and healthy individuals to determine QT and QTc

responses to HR and expand our understanding of arrhythmogenic risk in ATP1A3-D801N. Finally, we

convened a worldwide cohort of AHC cases to determine the risk of sinus node dysfunction and associated

outcomes.

METHODS

This was a retrospective study approved by the Duke University Hospitals Institutional Review Board, IRB

#Pro00094341. Informed consent was waived. In addition, retrospective data on AHC patients was

obtained using the International Consortium for Research on AHC and all the *ATP1A3* Rare Diseases

(IAHCRC), according to the rules of the IAHCRC Charter. All sites had ethics board or IRB approval.

Cohorts

<u>Primary Cohort</u>

The primary cohort consisted of consecutively enrolled individuals seen at Duke University Hospitals who

had undergone clinical evaluation and genetic testing for AHC. Individuals were included if they 1) met

full Aicardi diagnostic criteria for AHC[13], 2) met atypical/partial AHC diagnostic criteria and, 3) were

diagnosed with cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural deafness (CAPOS),

another disorder associated with *ATP1A3* mutations[17]. Individuals were excluded if they did not have 1) a

reported ECG, or 2) an ambulatory Holter monitoring report using HScribe[TM] software. Individuals in this

cohort were further categorized based on genotype as follows: ATP1A3-D801N; other pathogenic or likely

pathogenic single nucleotide variant in *ATP1A3*, defined as ATP1A3 non-D801N; presumed loss of

function variant in *ATP1A3* such as deletion or splice site variant, defined as *ATP1A3* LOF; and no likely

pathogenic or pathogenic *ATP1A3* variant detected on genetic testing, defined as genotype negative or

ATP1A3 Neg.

<u>Healthy Cohort</u>

Healthy individuals were selected for a comparison cohort if they were seen at Duke University Hospitals

for a cardiovascular evaluation. The following individuals were excluded: 1) elite athletes with documented

cardiovascular changes secondary to intense cardiovascular activity; 2) those with known congenital heart

disease, channelopathy, cardiomyopathy, and skeletal myopathy; 3) those with known genetic syndrome

with cardiac phenotype; 4) those taking cardiac medications, including antiarrhythmics; 5) those with an

abnormal ECG and/or echocardiogram; and 6) those with ventricular or supraventricular ectopy >1% of

total QRS complexes on Holter recording. All healthy individuals had undergone Holter monitoring with

HScribe™ software following cardiology visits for risk prediction due to identification of a genetic variant

associated with cardiac disease, family history of sudden cardiac arrest, cardiomyopathy, and/or

channelopathy, or history of arrhythmias or prolonged QT that had since resolved. Healthy individuals were

matched to AHC individuals based on sex and age (+/- 2 years).

IAHCRC Cohort

Given the rarity of AHC diagnoses, a multinational rare disease registry was established which consisted

of individuals from Duke University Hospitals as above, the IAHCRC, and the Baylor College of Medicine

(BCM). The cohort from the IAHCRC has been previously described[28]. Inclusion criteria for these

individuals included, 1) meeting full Aicardi diagnostic criteria for AHC as diagnosed by a neurologist[13],

2) meeting atypical/partial AHC diagnostic criteria, and 3) meeting criteria for other diagnoses, such as

rapid-onset dystonia-parkinsonism (RDP) or CAPOS, if they had a confirmed variant in *ATP1A3*[28].

Individuals were excluded from analysis if they 1) did not meet the inclusion criteria, 2) did not have

outcome data available, such as survival and pacemaker (PM) or PM/implantable cardioverter defibrillator

(ICD) implantation, and 3) did not have at least 1 ECG with original tracings available for re-review.

Holter Data Analysis

Holter data was collected from the Primary Cohort and Healthy Cohort using the HScribe™ cardiac

monitoring software. Holter recordings ranged in duration from 45 minutes to 24 hours. Automatically

generated minimum, mean, and maximum HR, QT, and QTc measurements over 5-minute intervals

throughout the Holter recording were abstracted. QTc was calculated using Bazett's correction[5]. A linear

regression analysis was performed for each Holter recording and genotype, and a line of fit equation was

calculated. Automated QT or QTc measurements that appeared to be outliers on visual inspection of linear

regression and were greater than 1.5 times the value of the line of fit equation for a given HR were

remeasured manually using Lepeschkin's method and Bazett's correction[5,29] and were excluded if they

differed. To validate the automated Holter recording measurements, >15% of total Holter recordings were

manually re-evaluated by two raters blinded to genotype using Lepeschkin's method and Bazett's

correction[5,29]. The average QT and QTc for every HR interval for each genotype were then assessed for

interrater agreement, defined as a difference of $\leq 10\%$ of the lower measurement, and Bland-Altman

analysis was performed. If there was >10% difference between measurements, the average of both

measurements was used for analysis. As a second method of validation, all ECGs for individuals in the

cohort were included in a replication analysis. The HR, QT, and QTc for each ECG were manually

measured by an electrophysiologist blinded to genotype. Linear regression analyses of HR vs QT and QTc

for individuals grouped by genotype were then performed.

<u>Outcomes Analysis</u>

We used Kaplan-Meier analysis to assess freedom from composite events, defined as 1) requiring a PM or

PM/ICD, or 2) having documented sinus pauses greater than 4 seconds, based on age at last follow-up. For

the Primary Cohort, this age was defined as age at last cardiology visit. For the IAHCRC Cohort, last

follow-up was defined as November 1, 2022, as the database was last updated through October 2022. For

those who had a composite event, age was defined as when they required device implantation or first had

sinus pauses greater than 4 seconds. For Holter analyses, we only included individuals with Holter data

available for review.

<u>Statistical Analysis</u>

Statistical analysis was performed using both JMP Pro 17 and Prism 10. Results are reported as mean $\pm$

standard deviation with 95% confidence intervals unless otherwise noted. A Kruskal-Wallis test with

Dunn's post-hoc multiple comparisons or Dunnet's post-hoc comparison to healthy was used for continuous

variables with more than two groups. Fisher's exact test was used for nominal variables with more than two

groups. Mann-Whitney test was used for continuous variables with two groups. Wilcoxon matched pairs

signed rank test was used to compare two groups with paired samples. Simple linear regression analysis

was modeled by the equation QT or QTc = mHR + b, where m is equivalent to slope and b is equivalent to

intercept. This analysis was conducted for overall linear regression for each genotype, as well as individual

linear regressions for each Holter recording and first diagnostic Holter recording. A mixed model was also

used to verify the genotype linear regression and account for repeated measurements from the same

individual. The HR, genotype, and interaction between HR and genotype were fixed effects, QT and QTc

were outcome variables, and subject number was a random effect with a residual repeated structure. Kaplan-

Meier analysis was compared using log-rank test. Significance was set at P= 0.05.

RESULTS

<u>Primary Cohort Characteristics</u>

To determine the relationship between cardiac repolarization time and HR, we first evaluated individuals

with AHC and healthy individuals recruited from Duke University Hospitals. In total, 44 individuals with

ATP1A3-related phenotypes and 36 healthy individuals were included in the Primary Cohort (**Table 1**). All

Holter recordings available in the HScribe™ software were utilized. Individuals with *ATP1A3*-related

phenotypes were grouped based on genotype as follows: ATP1A3-D801N (9 individuals, 25 Holter

recordings); ATP1A3 non-D801N (25 individuals, 38 Holter recordings); *ATP1A3* LOF (4 individuals, 9

Holter recordings); *ATP1A3* Neg (6 individuals, 9 Holter recordings). In the healthy group, 36 individuals

with 57 Holter recordings were included. We found no significant difference in mean age at first diagnostic

Holter and biological sex between genotypes (**Table 1**). Overall, <1% of data points from Holter recordings

were excluded.

<u>Individuals with ATP1A3-D801N show blunted QT change to heart rate variability</u>

Our group has previously shown that individuals with ATP1A3-D801N have shorter QTc on ECG compared to those with other variants[15]. Similarly, in our cohort, individuals with ATP1A3-D801N had an overall mean QT and QTc on Holter that were significantly lower than that of healthy individuals (302.68 $\pm$ 19.27 and 385.60 $\pm$ 27.95, vs 341.12 $\pm$ 32.36 and 426.96 $\pm$ 20.54, respectively; P <0.0001). Further, the mean QTc for ATP1A3-D801N was significantly lower than that of *ATP1A3* LOF and *ATP1A3* Neg. We then investigated HR modulation of QT interval in each group using a linear regression analysis. It is well established that the QT interval increases with reduced HR and decreases with increased HR[4,30] and that the QTc, which is corrected for HR, remains relatively constant across a range of HRs in healthy individuals[4,5]. We confirmed this observation in our healthy cohort which showed prolonged QT with slower HR and normalization of HR with QTc, demonstrated by a mean slope of HR vs QT of -1.52 and a mean slope of HR vs QTc of 0.22 (**Figures 1 and 2; Table 2**). Conversely, we found that individuals with ATP1A3-D801N exhibited diminished QT prolongation at lower HRs (**Figure 1; Figure S1; Table S1**). Specifically, we found that D801N probands had a lower mean linear regression slope than healthy individuals (-0.85 $\pm$ 0.46 vs -1.52 $\pm$ 0.42, respectively; P <0.0001; **Table 2**). For example, based on our model, at a mean HR of 60 beats per minute (bpm), D801N probands had a QT of 335.3ms. Conversely, healthy individuals had a mean QT of 396.6ms. These results were unique to individuals hosting the D801N variant. For example, individuals in the ATP1A3 non-D801N, *ATP1A3* LOF, and *ATP1A3* Neg genetic subgroups showed a similar QT vs HR relationship to healthy individuals (-1.24 $\pm$ 0.43, -1.41 $\pm$ 0.35, -1.41 $\pm$ 0.16, respectively, vs -1.52 $\pm$ 0.42; P value not significant). Further, each of these genotype groups showed less impairment of QT dynamics compared to ATP1A3-D801N (**Table 2**). To account for different numbers of Holter recordings per individual, this analysis was also replicated using only the first diagnostic Holter and demonstrated a similar relationship (**Figure S2; Table S2**). We then validated the automated QT measurements using manual measurements with 2 independent evaluators blinded to genotype. Again, we observed a blunted response of QT to lower HR in ATP1A3-D801N with strong interrater agreement (see

Supplemental Results; Figures S3-S4, Table S3). An independent validation using manual HR and

QT/QTc measurements from clinical ECGs blinded to genotype demonstrated a similar relationship

(**Figure S5**).

As several variables, including biological sex, can influence cardiac repolarization time[5,31], we next

conducted a sub-analysis to determine whether other variables might influence this finding. We found that

females with an *ATP1A3*-related phenotype, and those with ATP1A3 non-D801N variants, had a

significantly lower slope for HR vs QT compared to males, although it was a mild physiologic difference.

Further, there were no significant differences between male and females in all other groups (**Table S4**).

When analyzed by age, there was no significant difference in QT dynamics between individuals younger

than 10, 10–20, or older than 20 years old for ATP1A3-D801N or all *ATP1A3*-related phenotypes (**Table**

S5). Taken together, these findings suggest that individuals with ATP1A3-D801N have a blunted

prolongation of QT at lower HRs, while other genetic subtypes of AHC were more similar to healthy

individuals in their QT dynamics.

<u>Individuals with ATP1A3-D801N show paradoxical shortening of QTc interval at lower heart rates</u>

Given the diminished QT shortening with lower HRs demonstrated in the ATP1A3-D801N group, we

hypothesized that this group has an accentuated shortening of QTc at low HR when compared to healthy

individuals. Indeed, while control individuals demonstrated no significant change in QTc at lower heart

rates, we found that ATP1A3-D801N individuals had further shortening of the QTc (**Figure 2; Figure S6;**

Table S1), demonstrated by a greater mean slope than healthy individuals (0.80 ± 0.51 vs 0.22 ± 0.43,

respectively; P <0.0001; **Table 2**). For example, at a heart rate of 60bpm, the QTc for ATP1A3-D801N

was 356.7ms compared to 415.6ms in healthy individuals. As with QT, this relationship was similar when

replicated using only the first diagnostic Holter recordings for each individual and upon manual

measurement validation (**Supplemental Results; Figures S7-S9, Tables S2 and S6**). When linear

regression was performed for ECGs, there was also increased shortening of QTc at lower HR for ATP1A3-

D801N variant-positive individuals (**Figure S10).** Further, this blunted response was seen equally in both

D801N-positive males and females (**Table S7**), and there was no difference in QTc dynamics based on age

in individuals with *ATP1A3*-related phenotypes (**Table S8**). In summary, these results suggest that the

blunted QT prolongation with slower HR among individuals with ATP1A3-D801N is associated with a

paradoxical reduction of QTc at lower HRs compared to healthy controls and all other genetic subtypes of

ATP1A3-related phenotypes. We conclude that, given the already low QTc at baseline in these individuals,

bradycardia causes further reduction in QTc to a markedly abnormal range, exacerbating a known

arrhythmic risk factor.

<u>Individuals with QTc<350ms demonstrate blunted QT prolongation and QTc shortening with bradycardia</u>

We then investigated whether the maladaptive QT and QTc response to low HR is an ATP1A3-D801N

specific phenomenon, or whether individuals with other *ATP1A3* variants who have short QTc at baseline

also have this abnormal response. To do this, we separated individuals with *ATP1A3*-related phenotypes

into different groups defined by their baseline QTc on diagnostic ECG. Groups were defined using Gollob's

criteria[6], where normal QTc was between 370-470ms, borderline short QTc was between 350-370ms, and

short QTc was <350ms. Seven of the 44 patients with *ATP1A3*-related phenotypes had QTc <350ms. Four

of these hosted ATP1A3-D801N and the other 3 hosted ATP1A3 non-D801N variants (**Table S9**). None

of the individuals with *ATP1A3* LOF, *ATP1A3* Neg, or healthy individuals had QTc <350ms (**Table S9**).

We found that those with short diagnostic QTc (<350ms) had a diminished QT prolongation response to

HR compared to those with normal QTc (370-470ms), and the slope of HR vs QTc in the short QTc group

was significantly greater than that of the normal QTc group (**Figure 3; Table S9**). When separated by

specific genotype, there was greater impairment of HR vs QT dynamics in ATP1A3-D801N than in

ATP1A3 non-D801N for those with QTc <350ms. However, within each genotype, there was no significant

difference in QT or QTc dynamics when grouped by baseline QTc (see **Supplemental Results; Tables**

S10-S11). Taken together, we found that presence of short QTc of <350ms on diagnostic ECG for all

ATP1A3-related phenotypes is associated with greater impairment of QT and QTc dynamics. While this

effect was independent of genotype, most patients with QTc <350 hosted the ATP1A3-D801N variant.

<u>Individuals with *ATP1A3* variants are predisposed to significant sinus node dysfynction</u>

Given the association between bradycardia and QTc shortening, we next determined whether patients hosting *ATP1A3* variants were at increased risk of sinus node dysfunction[19]. To do this, we leveraged a large, multinational registry of individuals with AHC and *ATP1A3* genetic variants. The cohort was comprised of 131 individuals who met our inclusion/exclusion criteria: the same 44 individuals from Duke University Medical Center, 86 individuals from the IAHCRC, and 1 individual from BCM previously described in the literature[15]. Of these additional 87 individuals, 31 had available Holter recording measurements. Additional demographic characteristics for individuals from the IAHCRC and BCM are detailed in **Table S12**. We found no difference in sex or age representation among the genetic subgroups (**Table S12**). Individuals with ATP1A3-D801N reached an average maximum HR during Holter monitoring that was significantly lower than healthy individuals (153.94 ± 18.80 vs 176.21 ± 22.52; P <0.0001). Otherwise, there was no significant difference in average minimum HR, mean HR, and ventricular and supraventricular ectopy burden between any of the groups and healthy individuals (**Table 3**). We identified 3 out of 131 individuals who met the composite endpoint of implantation of a PM or PM/ICD or documented sinus pause, with a mean age at follow-up of 15.62 years (maximum of 50 years). Among them, 2 out of 3 hosted the D801N variant and the third hosted ATP1A3-S137F. For healthy individuals, *ATP1A3* LOF, and *ATP1A3* Neg, no individuals met the composite endpoint during the follow-up period. This yielded a calculated composite event rate of 0.15%/year/individual for the entire cohort, with a D801N-positive event rate of 0.38%/year/individual (**Figure 4**). Thus, leveraging the largest international cohort to date to explore this endpoint, we concluded that, although the frequency of significant sinus node dysfunction is low, individuals hosting the D801N variant have a greater predisposition to developing it compared to other genetic subtypes.

<u>Flunarizine may exacerbate the blunted QT response to bradycardia but does not worsen sinus node dysfunction</u>

Given that the standard of care for treatment of AHC involves the use of flunarizine[32,33], a T-type calcium

channel blocker, we next explored whether use of flunarizine was associated with exacerbation of the

cardiac phenotype observed, since its impact on the heart is unknown. Of the 131 individuals included, 90

were taking flunarizine and there was no significant difference between flunarizine use and the genetic

subtypes (**Table S13**). Among them, flunarizine use was not associated with changes in average minimum,

mean, or maximum HR for any genotype group when compared to those who were not taking flunarizine

(**Table S13**). When exploring the relationship between QT/QTc dynamics and flunarizine, we did find that

the overall slope for HR vs QTc was significantly greater for individuals with all *ATP1A3*-related

phenotypes taking flunarizine than for those who were not (**Table S13**). Specifically, we found that at a HR

of 60 bpm, the mean QTc was 376.97ms among those taking flunarizine versus 402.4ms among those not

taking flunairzine. This suggests that flunarizine might be associated with impairment of QT prolongation

during periods of bradycardia; however, the physiologic and clinical relevance of this finding is uncertain.

When separated by biological sex, the mean slope for HR vs QT among individuals taking flunarizine was

significantly lower in females than in males. At 60bpm, the mean QT in females taking flunarizine was

350.9ms versus 366.1ms in males, suggesting that flunarizine shortening of the QT interval might be

exacerbated in female patients (**Table S14**). This sex-bias was also observed for all patients with *ATP1A3*-

related phenotypes, regardless of flunarizine use (**Tables S4 and S7**). There was no difference in QT/QTc

dynamics based on flunarizine use for males (**Table S15**). However, females taking flunarizine had a

significantly lower slope for HR vs QT than females who were not not (**Table S16**). Taken together,

flunarizine may statistically impair QT dynamics during lower HR among specific subgroups of patients,

particularly among female individuals. Despite this statistical difference, the overall physiologic impact of

flunarizine on the heart remains unclear. This is particularly important as there is a clear role for flunarizine

in treating the neurologic manifestations of *ATP1A3*-related disease.

DISCUSSION

This study expands our understanding of arrhythmia risk in individuals with *ATP1A3*-related diseases, such

as AHC. In healthy individuals, the QT interval adapts to changes in HR by shortening when the HR

increases and lengthening when the HR decreases[4,30]. When correted by HR, the QTc remains relatively

fixed across a range of HRs among healthy individuals. We demonstrate that individuals with the ATP1A3-

D801N variant show impairment of this relationship with decreased prolongation of QT at lower HR,

similar to individuals diagnosed with SQTS[9,10]. This phenomenon has previously been described as

deceleration-dependent QT interval shortening[34,35]. One mechanistic explanation for this finding is that

increased acetylcholine inhibits the proper prolongation of QT when the HR slows[34,36]. Additionally,

inhibition of autonomic activity has been shown to cause impairment of QT dynamics[37]. Dysautonomia is

a minor diagnostic criterion for AHC[13] and could therefore be an explanation for the findings we describe

in ATP1A3-D801N. Overall, we uncover a potential novel mechanism of QT modulation that could

increase arrhythmia risk at lower HR, which seems to be based in a myocardial defect. However, the specific

details of how autonomic alterations further exacerbate risk is still unknown.

Correcting QT for HR can be done through a variety of different means[5,38-40]. Previous work has

demonstrated limitations to Bazett's correction in effectively normalizing the QTc during bradycardia and

tachycardia[41,42]. Importantly, we found that Bazett's correction held for all healthy individual HR ranges,

which include most HR ranges in our disease cohorts. Specifically, the slope of mean HR vs mean QTc for

healthy individuals was close to zero, indicating effective normalization of the QT for differences in HR

(**Figure 2**). From this, we ultimately concluded that the automated Bazett's correction formula was suitable

for correcting QT in all groups. In addition, we assessed association of changes in QT and QTc dynamics

with factors such as biological sex, age, and flunarizine use. While we found a difference in HR vs QT

between males and females, there was no difference in HR vs QTc, suggesting that HR variation might

manifest as a difference in QT responsiveness that subsides with QT correction for HR. Age did not seem

to have an effect, whereas flunarizine use showed a small effect on HR vs QTc dynamics. However, we see

no clear evidence that flunarizine negatively impacts the heart. Moreover, it is the medication of choice for

alleviation of neurologic symptoms in AHC, therefore the known benefits are significantly greater than any

harms.

Given the finding that individuals with ATP1A3-D801N have short QTc at baseline[15,16], which is a known

arrhythmia risk[1-3], we saught to determine the affect of heart rate on this QT abnormality. We found that

individuals with *ATP1A3*-related phenotypes who also had a short baseline QTc demonstrated impairment

of normal QT dyanmics with changing in HR, particularly during periods of bradycardia. This results in a

shortening of the QTc at lower HR, which exacerbates the short QT phenotype further. It is likely that this

is the proarrhythmic trigger for many patients who have had a life-threatening arrhythmic event with

ATP1A3-related disease. As such, it is critical that patients with AHC, and anyone with an *ATP1A3*

mutation, are evaluated by an electrophysiology and cardiovascular genetic specialist to determine their

QT/QTc at baseline. This clincal evaluation, when combined with genetic risk assessment, is key to

determining the risk for arrhythmias. Furthermore, with increasing knowledge of the cardiac manifestations

of AHC, questions arise as to whether these individuals are at risk of sinus node dysfunction requiring PM

or ICD implantation. Analysis of our combined cohort shows that sinus node dysfunction is uncommon,

with few individuals requiring a device or experiencing significant sinus pauses. While the risk is low,

events can be severe when they do occur, and our results indicate a greater event rate in those with ATP1A3-

D801N. Thus, it is crucial to universally check and routinely monitor sinus node dysfunction in these

individuals through ambulatory monitoring. Further, as sinus bradycardia resulting from sinus node

dysfunction might compound the risk in patients with the D801N variant and short QT, this may represent

another pro-arrhythmic variable.

We acknowledge limitations to our study design and methodology. As this is a retrospective study, it is

unclear if abnormal QT and QTc dynamics with decreasing HR are directly responsible for arrhythmias in

individuals with ATP1A3-D801N. Future directions include exploring rate dependency in human induced

pluripotent stem cell cardiomyocytes (iPSC-CMs) from individuals with ATP1A3-D801N to better

characterize this mechanism. Additionally, AHC is a rare disease and our cohort is small. As a result, we

may be underpowered to detect certain differences. However, this is the largest study to date of Holter

recordings from patients with AHC across a multinational registry. Finally, rather than using beat-to-beat

data, our study utilizes five-minute averages of HR, QT, and QTc provided by the Holter monitoring

software. Although this provides us with less data than would otherwise be available, we were still able to

detect a significant difference in relationships between ATP1A3-D801N and healthy.

CONCLUSIONS

Overall, our findings support the idea that AHC, and specifically the ATP1A3-D801N variant, can manifest

as a cardiac phenotype resembling SQTS. It is important to advise individuals with ATP1A3-D801N,

particularly those with very short baseline QTc on ECG, of the risk of arrhythmia with slowed HR, such as

during sedation or anesthesia. Currently, there is no treatment for abnormal QT and QTc dynamics,

although quinidine has been proposed for patients with SQTS[10]. For now, cardiac monitoring during periods

of possible low HR is advised.

ACKNOWLEDGEMENTS

Thank you to all contributors to the IAHCRC. Dr. Andrew Landstrom had full access to all the data in the

study and takes responsibility for data integrity and accuracy of data analysis.

SOURCES OF FUNDING

MKB is supported by The Paul Gillette PACES Research Grant and by National Institute of Health (NIH)

T32 GM007171. APL is supported by National Institutes of Health (R01-HL160654, R01-HL166217),

Doris Duke Charitable Foundation (CSDA-2020098), John Taylor Babbitt Foundation, The Hartwell

Foundation, Additional Ventures, Y.T. and Alice Chen Pediatric Genetics and Genomics Research Center.

DISCLOSURES

MAM has intellectual property interest in gene therapy for *ATP1A3*-related disease pending patent

application.

SUPPLEMENTAL MATERIAL

Tables S1–S16

Figures S1-S10

480   **REFERENCES**
481   1.   Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR, Bjerregaard P.
482   Idiopathic Short QT Interval:A New Clinical Syndrome? *Cardiology*. 2001;94:99-102.
483   doi: 10.1159/000047299
484   2.   Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, Probst V, Blanc J-
485   J, Sbragia P, Dalmasso P, et al. Long-Term Follow-Up of Patients With Short QT
486   Syndrome. *Journal of the American College of Cardiology*. 2011;58:587-595. doi:
487   https://doi.org/10.1016/j.jacc.2011.03.038
488   3.   Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, Grossi S, Richiardi E,
489   Borggrefe M. Short QT Syndrome. *Circulation*. 2003;108:965-970. doi:
490   doi:10.1161/01.CIR.0000085071.28695.C4
491   4.   Seed WA, Noble MI, Oldershaw P, Wanless RB, Drake-Holland AJ, Redwood D, Pugh S,
492   Mills C. Relation of human cardiac action potential duration to the interval between
493   beats: implications for the validity of rate corrected QT interval (QTc). *Br Heart J*.
494   1987;57:32-37. doi: 10.1136/hrt.57.1.32
495   5.   Bazett H. An analysis of the time-relations of. *Heart*. 1920;7:353.
496   6.   Gollob MH, Redpath CJ, Roberts JD. The Short QT Syndrome: Proposed Diagnostic
497   Criteria. *Journal of the American College of Cardiology*. 2011;57:802-812. doi:
498   https://doi.org/10.1016/j.jacc.2010.09.048
499   7.   Ploneda-Valencia RG, Ortiz-Solis WA, Ruiz-Gonzalez G, Santiago-Garcia AK, Rivera-
500   Rodríguez L, Nava-Townsend S, Márquez MF, Levinstein-Jacinto M. Supraventricular
501   tachyarrhythmia and sinus node dysfunction as a first manifestation of short QT
502   syndrome in a pediatric patient. Case Report. *J Electrocardiol*. 2022;74:146-153. doi:
503   10.1016/j.jelectrocard.2022.08.010
504   8.   Righi D, Silvetti MS, Drago F. Sinus bradycardia, junctional rhythm, and low-rate atrial
505   fibrillation in Short QT syndrome during 20 years of follow-up: three faces of the same
506   genetic problem. *Cardiology in the Young*. 2016;26:589-592. doi:
507   10.1017/S1047951115001432
508   9.   Giustetto C, Scrocco C, Schimpf R, Maury P, Mazzanti A, Levetto M, Anttonen O,
509   Dalmasso P, Cerrato N, Gribaudo E, et al. Usefulness of exercise test in the diagnosis of
510   short QT syndrome. *Europace*. 2015;17:628-634. doi: 10.1093/europace/euu351
511   10.   Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R,
512   Hong K, Bauersfeld U, Gaita F, Borggrefe M. Further insights into the effect of quinidine
513   in short QT syndrome caused by a mutation in HERG. *J Cardiovasc Electrophysiol*.
514   2005;16:54-58. doi: 10.1046/j.1540-8167.2005.04470.x
515   11.   Redpath CJ, Green MS, Birnie DH, Gollob MH. Rapid genetic testing facilitating the
516   diagnosis of short QT syndrome. *Can J Cardiol*. 2009;25:e133-135. doi: 10.1016/s0828-
517   282x(09)70077-7
518   12.   Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM,
519   Brugada J, Pollevick GD, Wolpert C, et al. Sudden Death Associated With Short-QT
520   Syndrome Linked to Mutations in HERG. *Circulation*. 2004;109:30-35. doi:
521   doi:10.1161/01.CIR.0000109482.92774.3A
522   13.   Mikati MA, Panagiotakaki E, Arzimanoglou A. Revision of the diagnostic criteria of
523   alternating hemiplegia of childhood. *Eur J Paediatr Neurol*. 2021;32:A4-a5. doi:
524   10.1016/j.ejpn.2021.05.004
525   14.   Panagiotakaki E, Gobbi G, Neville B, Ebinger F, Campistol J, Nevšímalová S, Laan L,
526   Casaer P, Spiel G, Giannotta M, et al. Evidence of a non-progressive course of alternating

527   hemiplegia of childhood: study of a large cohort of children and adults. *Brain*.
528   2010;133:3598-3610. doi: 10.1093/brain/awq295

529   15.   Moya-Mendez ME, Ogbonna C, Ezekian JE, Rosamilia MB, Prange L, Uz Cdl, Kim JJ,
530   Howard T, Garcia J, Nussbaum R, et al. ATP1A3-Encoded Sodium-Potassium ATPase
531   Subunit Alpha 3 D801N Variant Is Associated With Shortened QT Interval and
532   Predisposition to Ventricular Fibrillation Preceded by Bradycardia. *Journal of the*
533   *American Heart Association*. 2021;10:e019887. doi: doi:10.1161/JAHA.120.019887

534   16.   Jaffer F, Avbersek A, Vavassori R, Fons C, Campistol J, Stagnaro M, De Grandis E,
535   Veneselli E, Rosewich H, Gianotta M, et al. Faulty cardiac repolarization reserve in
536   alternating hemiplegia of childhood broadens the phenotype. *Brain*. 2015;138:2859-2874.
537   doi: 10.1093/brain/awv243

538   17.   Masoud M, Prange L, Wuchich J, Hunanyan A, Mikati MA. Diagnosis and Treatment of
539   Alternating Hemiplegia of Childhood. *Current Treatment Options in Neurology*.
540   2017;19:8. doi: 10.1007/s11940-017-0444-7

541   18.   Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, Tiziano FD,
542   Fontaine B, Walley NM, Heavin S, et al. De novo mutations in ATP1A3 cause alternating
543   hemiplegia of childhood. *Nat Genet*. 2012;44:1030-1034. doi: 10.1038/ng.2358

544   19.   Balestrini S, Mikati MA, Alvarez-Garcia-Roves R, Carboni M, Hunanyan AS, Kherallah
545   B, McLean M, Prange L, De Grandis E, Gagliardi A, et al. Cardiac phenotype in
546   ATP1A3-related syndromes: A multicenter cohort study. *Neurology*. 2020;95:e2866-
547   e2879. doi: 10.1212/WNL.0000000000010794

548   20.   Novy J, McWilliams E, Sisodiya SM. Asystole in alternating hemiplegia with de novo
549   ATP1A3 mutation. *European Journal of Medical Genetics*. 2014;57:37-39. doi:
550   https://doi.org/10.1016/j.ejmg.2013.11.003

551   21.   Parker LE, Wallace K, Thevathasan A, Funk E, Pratt M, Thamby J, Tran L, Prange L,
552   Uchitel J, Boggs A, et al. Characterization of sedation and anesthesia complications in
553   patients with alternating hemiplegia of childhood. *European journal of paediatric*
554   *neurology : EJPN : official journal of the European Paediatric Neurology Society*.
555   2022;38:47-52. doi: 10.1016/j.ejpn.2022.03.007

556   22.   Thamby J, Prange L, Boggs A, Subei MO, Myers C, Uchitel J, ElMallah M, Bartlett-Lee
557   B, Riviello JJ, Mikati MA. Characteristics of non-sleep related apneas in children with
558   alternating hemiplegia of childhood. *Eur J Paediatr Neurol*. 2024;48:101-108. doi:
559   10.1016/j.ejpn.2023.12.002

560   23.   Kligfield P, Lax KG, Okin PM. QT interval-heart rate relation during exercise in normal
561   men and women: Definition by linear regression analysis. *Journal of the American*
562   *College of Cardiology*. 1996;28:1547-1555. doi: https://doi.org/10.1016/S0735-
563   1097(96)00351-8

564   24.   Tavernier R, Jordaens L, Haerynck F, Derycke E, Clement DL. Changes in the QT
565   interval and its adaptation to rate, assessed with continuous electrocardiographic
566   recordings in patients with ventricular fibrillation, as compared to normal individuals
567   without arrhythmias. *Eur Heart J*. 1997;18:994-999. doi:
568   10.1093/oxfordjournals.eurheartj.a015389

569   25.   Merri M, Moss AJ, Benhorin J, Locati EH, Alberti M, Badilini F. Relation between
570   ventricular repolarization duration and cardiac cycle length during 24-hour Holter
571   recordings. Findings in normal patients and patients with long QT syndrome. *Circulation*.
572   1992;85:1816-1821. doi: doi:10.1161/01.CIR.85.5.1816

26. Larroude CE, Jensen BT, Agner E, Toft E, Torp-Pedersen C, Wachtell K, Kanters JK.
Beat-to-beat QT dynamics in paroxysmal atrial fibrillation. *Heart Rhythm*. 2006;3:660-
664. doi: https://doi.org/10.1016/j.hrthm.2006.02.021
27. Magnano AR, Holleran S, Ramakrishnan R, Reiffel JA, Bloomfield DM. Autonomic
nervous system influences on qt interval in normal subjects. *Journal of the American*
College of Cardiology. 2002;39:1820-1826. doi: doi:10.1016/S0735-1097(02)01852-1
28. Moya-Mendez ME BM, Zhang Z, Ezekian JE, Perelli RM, Parker LE, Prange L, Boggs
A, et al. ATP1A3 Variants are Associated with Variably Penetrant Short QT and Lethal
Ventricular Arrhythmias. *In submission* 2024.
29. LEPESCHKIN E, SURAWICZ B. The Measurement of the Q-T Interval of the
Electrocardiogram. *Circulation*. 1952;6:378-388. doi: doi:10.1161/01.CIR.6.3.378
30. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and
the use of Bazett's formula in myocardial infarction. *Am Heart J*. 1985;109:568-574. doi:
10.1016/0002-8703(85)90564-2
31. Merri M, Benhorin J, Alberti M, Locati E, Moss AJ. Electrocardiographic quantitation of
ventricular repolarization. *Circulation*. 1989;80:1301-1308. doi: 10.1161/01.cir.80.5.1301
32. Mikati MA, Kramer U, Zupanc ML, Shanahan RJ. Alternating hemiplegia of childhood:
clinical manifestations and long-term outcome. *Pediatr Neurol*. 2000;23:134-141. doi:
10.1016/s0887-8994(00)00157-0
33. Casaer P, Azou M. Flunarizine in alternating hemiplegia in childhood. *Lancet*.
1984;2:579. doi: 10.1016/s0140-6736(84)90794-3
34. Gussak I, Liebl N, Nouri S, Bjerregaard P, Zimmerman F, Chaitman BR. Deceleration-
dependent shortening of the QT interval: a new electrocardiographic phenomenon? *Clin*
Cardiol. 1999;22:124-126. doi: 10.1002/clc.4960220213
35. Takahashi N, Ito M, Ishida S, Nakagawa M, Hara M, Saikawa T, Sakata T. Paradoxically
shortened QT interval after a prolonged pause. *Pacing Clin Electrophysiol*.
1998;21:1476-1479. doi: 10.1111/j.1540-8159.1998.tb00221.x
36. DiFrancesco D, Ducouret P, Robinson RB. Muscarinic Modulation of Cardiac Rate at
Low Acetylcholine Concentrations. *Science*. 1989;243:669-671. doi:
doi:10.1126/science.2916119
37. Cappato R, Alboni P, Codecà L, Guardigli G, Toselli T, Antonioli GE. Direct and
autonomically mediated effects of oral quinidine on RR/QT relation after an abrupt
increase in heart rate. *J Am Coll Cardiol*. 1993;22:99-105. doi: 10.1016/0735-
1097(93)90822-i
38. FRIDERICIA LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen
und bei Herzkranken. *Acta Medica Scandinavica*. 1920;53:469-486. doi:
https://doi.org/10.1111/j.0954-6820.1920.tb18266.x
39. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for
adjusting the QT interval for heart rate (the Framingham Heart Study). *American Journal*
of Cardiology. 1992;70:797-801. doi: 10.1016/0002-9149(92)90562-D
40. Hodges M. Bazett's QT correction reviewed-Evidence that a linear QT correction for
heart is better. In: *Journal of the American College of Cardiology*. 1983:694.
41. Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT
correction formulae: The effect of heart rate on the QTc of normal ECGs. *Journal of*
Electrocardiology. 2004;37:81-90. doi: https://doi.org/10.1016/j.jelectrocard.2004.08.030

42.   MALIK M, HNATKOVA K, BATCHVAROV V. Differences Between Study-Specific
and Subject-Specific Heart Rate Corrections of the QT Interval in Investigations of Drug
Induced QTc Prolongation. *Pacing and Clinical Electrophysiology*. 2004;27:791-800.
doi: https://doi.org/10.1111/j.1540-8159.2004.00530.x

TABLES

Table 1. Primary cohort characteristics.

	Healthy	*ATP1A3*-Related Phenotype*	ATP1A3-D801N	ATP1A3 Non-D801N	*ATP1A3* LOF [†]	*ATP1A3* Neg [‡]	P value
Number of Individuals	36	44	9	25	4	6	
Number of Holter Recordings	57	81	25	38	9	9	
Sex (% F)	52.78	52.27	55.56	52.00	50.00	50.00	>0.9999
Mean Age at First Holter (SD)	9.84 (7.94)	8.04 (8.50)	4.28 (4.93)	9.78 (10.26)	3.23 (1.91)	9.67 (3.50)	0.16

[*]Includes individuals with a formal diagnosis of AHC (n=37) or CAPOS (n=1), those who did not meet full criteria for AHC but were found to host an *ATP1A3* variant (n=5), and one individual with no variant in *ATP1A3* who did not meet full criteria for AHC (n=1). [†]Includes individuals with deletion (n=3) or splice site variant in *ATP1A3* (n=1). [‡]Includes individuals with no pathogenic or likely pathogenic variant in *ATP1A3* identified (n=6). P values were calculated using Fisher's exact test or Kruskal-Wallis test. LOF, loss of function variant; Neg, genotype negative.

Table 2. Mean slope of linear regression for HR versus QT and QTc, compared by genotype.

	Healthy	ATP1A3-D801N	ATP1A3 Non-D801N	*ATP1A3* LOF	*ATP1A3* Neg	P value
n	57	25	38	9	9	
Mean Slope HR vs QT	-1.52 ± 0.42 (-1.63 – -1.41)	-0.85 ± 0.46 (-1.03 – -0.67)	-1.24 ± 0.43 (-1.37 – -1.10)	-1.41 ± 0.35 (-1.64 – -1.19)	-1.41 ± 0.16 (-1.52 – -1.30)	<0.0001*
Mean Slope HR vs QTc	0.22 ± 0.43 (0.11 – 0.33)	0.80 ± 0.51 (0.60 – 1.00)	0.52 ± 0.46 (0.38 – 0.67)	0.20 ± 0.50 (-0.13 – 0.53)	0.32 ± 0.22 (0.18 – 0.47)	<0.0001*

*Healthy compared to ATP1A3-D801N, using Kruskal-Wallis test with Dunnet's post-hoc comparison to healthy. Values listed as mean ± SD (95% confidence interval). HR, heart rate; QTc, corrected QT; LOF, loss of function variant; Neg, genotype negative.

Table 3. Holter recording characteristics for all individuals from primary and IAHCRC cohorts.

	Healthy	ATP1A3-D801N	ATP1A3 Non-D801N	*ATP1A3* LOF	*ATP1A3* Neg	P value
Number of Individuals (Holter recordings)	36 (57)	19 (36)	47 (58)	5 (10)	7 (10)	
Sex (% Female)	52.78	57.89	53.19	60.00	57.14	0.98
Mean Age at First Holter (SD)	9.84 (7.94)	13.75 (12.58)	10.98 (10.16)	5.35 (5.02)	12.85 (9.00)	0.44
Minimum HR (SD)	57.18 (8.30)	51.39 (7.48)	55.72 (9.84)	55.80 (8.92)	59.60 (5.38)	0.03
Mean HR (SD)	95.61 (6.53)	92.54 (12.98)	93.95 (16.80)	104.60 (10.12)	94.90 (8.74)	0.18
Maximum HR (SD)	176.21 (22.52)	153.94 (18.80)	159.05 (19.84)	166.70 (17.11)	168.10 (16.67)	**<0.0001**
Longest RR (SD)	1.26 (0.22)	1.57 (0.48)	1.30 (0.24)	1.48 (0.61)	1.28 (0.21)	**0.008**
VE/Hour	0.50 (3.29)	0.00* (0.08)	0.51 (3.55)	0.37 (1.10)	0.00 (0.00)	0.11
SVE/Hour	0.12 (0.24)	1.65 (7.25)	2.62 (14.38)	0.22 (0.71)	0.034 (0.048)	0.09

Heart rates are listed in beats per minute (BPM), RR is listed in seconds. *Listed as median (interquartile range), as one individual had 1102 VE per hour (23157 total). P value calculated with Fisher's exact test or Kruskal-Wallis test with Dunn's post-hoc multiple comparisons. HR, heart rate; VE, ventricular ectopy; SVE, supraventricular ectopy; LOF, loss of function variant; Neg, genotype negative.

FIGURES

Figure 1. ATP1A3-D801N is associated with blunted response of QT to lower HR compared to healthy. Linear regression analysis of mean HR versus mean QT over five-minute intervals throughout each Holter recording for individuals in the primary and healthy cohorts. Colored points represent individual data points for all Holter recordings included in each genotype group. Solid line represents overall linear regression line of fit. m represents slope of the line of fit equation. A. Healthy cohort (n=57), QT= -1.64HR + 501.40; R^2= 0.70. B. ATP1A3-D801N subgroup (n=25), QT= -0.79HR + 381.50; R^2= 0.32. C. ATP1A3 non-D801N subgroup (n=38), QT= -1.27HR + 445.10; R^2= 0.45. D. *ATP1A3* LOF subgroup (n=9), QT= -1.28HR + 465.50; R^2= 0.61. E. *ATP1A3* Neg subgroup (n=9), QT= -1.44HR + 483.80; R^2= 0.80. F. Overall lines of fit for each of the respective subgroups. Blue, healthy; black, ATP1A3-D801N; red, ATP1A3 non-D801N; purple, *ATP1A3* LOF; orange, *ATP1A3* Neg.

Figure 2. ATP1A3-D801N is associated with increased shortening of QTc at lower HR compared to healthy. Linear regression analysis of mean heart rate versus mean QTc over five-minute intervals throughout Holter recording for individuals in the primary and healthy cohorts. Colored points represent individual data points for all Holter recordings included in each genotype group. Solid line represents overall linear regression line of fit. m represents slope of the line of fit equation. A. Healthy (n=57), QTc= 0.06HR + 421.80; R^2= 0.0023. B. ATP1A3-D801N (n=25), QTc= 0.96HR + 291.40; R^2= 0.30. C. ATP1A3 non-D801N (n=38), QTc= 0.42HR + 362.10; R^2= 0.055. D. ATP1A3 LOF (n=9), QTc= 0.41HR + 390.40; R^2= 0.083. E. ATP1A3 Neg (n=9), QTc= 0.28HR + 406.30; R^2= 0.093. F. Lines of fit for all groups. Blue, healthy; black, ATP1A3-D801N; red, ATP1A3 non-D801N; purple, *ATP1A3* LOF; orange, *ATP1A3* Neg.

Figure 3. Short baseline QTc is associated with greater impairment of QT and QTc dynamics. Each colored line represents the linear regression for Holter recordings from individuals in the primary and

healthy cohorts with a given baseline QTc on ECG. A. Mean HR versus mean QT for Holter recordings from individuals with *ATP1A3*-related phenotypes (n=81) compared to healthy patients (n=57). B. Mean HR versus mean QTc for Holter recordings from individuals with *ATP1A3*-related phenotypes (n=81) compared to healthy (n=57). Black, <350ms (n=16); red, 350-370ms (n=15); purple, 370-470ms (n=50); blue, healthy, all 370-470ms (n=57).

Figure 4. ATP1A3-D801N is associated with sinus node dysfunction. A. Kaplan-Meier analysis of freedom from composite events versus age of event in individuals from primary and IAHCRC cohorts (n=131), as compared to those from the healthy cohort (n=36). Tick marks represent censored individuals. Bars represent 95% confidence intervals. No significant difference between healthy and *ATP1A3*-related phenotype using log-rank test (P = 0.57). B. Characteristics of individuals who had composite events. PM, pacemaker; ICD, implantable cardioverter defibrillator.

Age at Event (y)	Genotype	Composite Event
4.5	ATP1A3-D801N	Sinus pauses >4s, cardiac arrest
23	ATP1A3-S137F	PM for episodes of sinus arrest
26	ATP1A3-D801N	Sinus pauses >4s, PM/ICD for sinus node dysfunction, 3rd degree AV block, syncope

B